Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.
2.

Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.

Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, Heath L, Weiner D, Mullins JI.

J Virol. 2007 Aug;81(16):8507-14. Epub 2007 May 30.

3.

Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles.

Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK, Little S, Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M.

J Virol. 2007 Jul;81(14):7725-31. Epub 2007 May 9.

4.

Founder effects in the assessment of HIV polymorphisms and HLA allele associations.

Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, Carlson J, Yusim K, McMahon B, Gaschen B, Mallal S, Mullins JI, Nickle DC, Herbeck J, Rousseau C, Learn GH, Miura T, Brander C, Walker B, Korber B.

Science. 2007 Mar 16;315(5818):1583-6.

5.

Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference.

Larke N, Im EJ, Wagner R, Williamson C, Williamson AL, McMichael AJ, Hanke T.

Eur J Immunol. 2007 Feb;37(2):566-77.

6.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT.

Nat Med. 2007 Jan;13(1):100-6. Epub 2006 Dec 24.

PMID:
17187074
7.

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.

Hanke T, Goonetilleke N, McMichael AJ, Dorrell L.

J Gen Virol. 2007 Jan;88(Pt 1):1-12. Review. Erratum in: J Gen Virol. 2008 Feb;89(Pt 2):609. Goonetilleke, Nilu [added].

PMID:
17170430
8.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1650-60. Epub 2006 Nov 8.

9.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1638-49. Epub 2006 Nov 8. Erratum in: J Infect Dis. 2009 Oct 15;200(8):1352-3.

10.

Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Mestecky J, Gao F, Haynes BF, Shaw GM, Muldoon M, Korber BT, Hahn BH.

Virology. 2007 Mar 30;360(1):218-34. Epub 2006 Nov 13.

11.

HIV vaccines: new frontiers in vaccine development.

Duerr A, Wasserheit JN, Corey L.

Clin Infect Dis. 2006 Aug 15;43(4):500-11. Epub 2006 Jul 6. Review.

12.

Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, Ma BJ, Muldoon M, Theiler J, Nabel GJ, Letvin NL, Korber BT, Hahn BH, Haynes BF, Gao F.

J Virol. 2006 Jul;80(14):6745-56.

13.

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Haynes BF, Shaw GM, Korber BT, Hahn BH.

Virology. 2006 Sep 1;352(2):438-49. Epub 2006 Jun 14.

14.

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach V, Roberts J, Guimaraes-Walker A, Hayes P, Loughran K, Smith C, De Bont J, Verlinde C, Vooijs D, Schmidt C, Boaz M, Gilmour J, Fast P, Dorrell L, Hanke T, McMichael AJ.

J Virol. 2006 May;80(10):4717-28.

15.

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Bowness P, Goonetilleke N, Rostron T, Rowland-Jones S, Hanke T, McMichael A.

J Virol. 2006 May;80(10):4705-16.

16.

HIV vaccines.

McMichael AJ.

Annu Rev Immunol. 2006;24:227-55. Review.

PMID:
16551249
18.

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes.

Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C.

Nat Immunol. 2006 Feb;7(2):173-8. Epub 2005 Dec 20.

PMID:
16369537
19.

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.

Slyker JA, Lohman BL, Mbori-Ngacha DA, Reilly M, Wee EG, Dong T, McMichael AJ, Rowland-Jones SL, Hanke T, John-Stewart G.

Vaccine. 2005 Sep 7;23(38):4711-9. Epub 2005 Feb 19.

20.
Items per page

Supplemental Content

Write to the Help Desk